None
Quote | Phio Pharmaceuticals Corp. (NASDAQ:PHIO)
Last: | $5.2447 |
---|---|
Change Percent: | 803.01% |
Open: | $5 |
Close: | $0.5808 |
High: | $5.45 |
Low: | $4.71 |
Volume: | 29,539 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Phio Pharmaceuticals Corp. (NASDAQ:PHIO)
2024-07-05 08:38:30 ET More on Phio Pharmaceuticals Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceuticals Read the full article on Seeking Alpha For...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...
Message Board Posts | Phio Pharmaceuticals Corp. (NASDAQ:PHIO)
Subject | By | Source | When |
---|---|---|---|
8k | Awl416 | investorshub | 05/16/2023 11:48:58 AM |
MomentumIts now | trendzone | investorshub | 05/15/2023 9:25:10 AM |
The trading | surf1944 | investorshub | 05/14/2023 8:47:54 PM |
$PHIO what does this mean? | trendzone | investorshub | 05/14/2023 7:38:00 PM |
$PHIO just the news we needed | knrorrel | investorshub | 05/06/2023 1:54:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
803.01%Change Percent:
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...
2024-07-04 09:02:05 ET Phio Pharmaceuticals Corp (PHIO) announced stock split at a ratio of 1-for-9 on 2024-07-05 ... Full story available on KlickAnalytics.com
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ® siRNA gene silencing techno...